This therapy greatly improves the activity of CAR‐T cells and improves the survival rate of cholangiocarcinoma model mice in vivo.[399] Another CAR T cell therapy targeting EGFR and interleukin‐13 receptor α2 (IL13Rα2) was applied in recurrent glioblastoma, whose median OS is less than 1 year. This evidence concerns the gene EGFR and glioblastoma.